Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia.

Abstract

Two different doses of quinupristin/dalfopristin were compared with intravenous vancomycin with regard to the efficacy and safety in the treatment of catheter-related staphylococcal bacteremia. A total of 39 patients were enrolled from 13 centers. For all treated patients with a baseline pathogen, outcome was comparable for all antibiotic study regimens. Discontinuation of the antibiotic for an adverse clinical event occurred in 12% of patients receiving quinupristin/dalfopristin and in 15% of those receiving vancomycin. Quinupristin/dalfopristin may have the potential to serve as an alternative agent in the treatment of catheter-related staphylococcal bacteremia. However, larger prospective randomized trials are required.

• Authors: I Raad, F Bompart, R Hachem
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 18 Issue 3 Pg. 199-202 (Mar 1999) ISSN: 0934-9723 [Print] Germany
• PMID: 10357054 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Virginiamycin
• quinupristin
• Vancomycin
• dalfopristin

Topics

• Adult
• Aged
• Anti-Bacterial Agents (administration & dosage, therapeutic use)
• Bacteremia (drug therapy, etiology)
• Catheterization (adverse effects)
• Drug Administration Schedule
• Drug Therapy, Combination (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Pilot Projects
• Prospective Studies
• Single-Blind Method
• Staphylococcal Infections (drug therapy, etiology)
• Vancomycin (therapeutic use)
• Virginiamycin (administration & dosage, analogs & derivatives, therapeutic use)